Abstract: Compounds of formula I and II: or a pharmaceutically acceptable salt thereof, and their compositions including polymer encapsulated micro/nano particle compositions are provided, wherein: R1 is —CH2—, a C2-6 straight or branched chain alkylene, alkenylene or alkynylene group or a short chain polyethylene glycol group having 2-6 monomers, or a combination thereof; R2 is hydrogen or —(C?O)R3 wherein R3 is a C2-6 straight or branched chain alkylene, alkenylene or alkynylene group or a short chain polyethylene glycol group having 2-6 monomers, or a combination thereof; and R4 is a pharmaceutically acceptable polymeric moiety comprising a pharmaceutically acceptable polymer chain such that R1 is linked to the polymer chain through an ester, carbonate or carbamate bond including the oxygen atom linking R1 and R4. The compositions are useful for treatment of multiple myeloma, mantle cell lymphoma, and transfusion-dependent anemia due to myelodysplastic syndromes.

Abstract: The present invention provides compositions comprising PAMAM dendrimers conjugated with one or more biologically active agents, and their use systemically to target activated microglia/macrophages in retina/choroid and generally, inflammatory and/or angiogenic diseases of the eye.

Abstract: The present invention comprises compounds of formula (I): where R1 may be PEG or other polymeric moieties. For example, R1 may be repeating PEG units —(CH2—CH2—O)n—, wherein n=1-455. R1 may also be other polymeric moieties of varying sizes and structures, for example, R1 may be poly(glycolide), poly(lactic acid), poly(lactide), poly(caprolactone), poly(lactide-co-caprolactone), poly(lactide-co-glycolide), or poly(lactic acid)-butanol. One or more embodiments of the invention may also relate to injectable pharmaceutical compositions comprising polymer conjugated monomethyl fumarate, and methods for treating relapsing-remitting multiple sclerosis and psoriasis.

Abstract: The present invention provides compositions comprising PAMAM dendrimers conjugated with one or more biologically active agents, and their use systemically to target activated microglia/macrophages in retina/choroid and generally, inflammatory and/or angiogenic diseases of the eye.

Abstract: In one embodiment, an apparatus may receive metadata that is associated with content. The metadata includes event descriptors that describe events included in the content. The apparatus may generate a question based on at least one of the event descriptors.

Abstract: In one embodiment, an apparatus may receive metadata that is associated with content. The metadata includes event descriptors that describe events included in the content. The apparatus may generate a question based on at least one of the event descriptors.